Using HER2 PET imaging to improve treatment for bladder cancer
Official title: HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma
Funded at Sloan-Kettering Inst Can Research · NIH-11061006 · Data updated 2026-11-12
This study is looking at how a special imaging technique can help doctors see differences in a protein called HER2 in bladder cancer, which might help them figure out the best treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $556,762 |
| NIH project number | 5R01CA288692-02 |
| Project ID | NIH-11061006 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic urothelial carcinoma who exhibit HER2 expression.
✕Less likely to help
Patients with non-metastatic bladder cancer or those without HER2 expression may not benefit from this research.
What this research studies
This research investigates how HER2 PET imaging can help assess the variability of HER2 expression in bladder cancer and predict how well patients will respond to targeted therapies. By examining both primary and metastatic tumors, the study aims to identify differences in HER2 expression that could influence treatment outcomes. The approach involves using advanced imaging techniques to visualize HER2 levels, which may guide personalized treatment plans for patients with urothelial carcinoma. Ultimately, the goal is to enhance the effectiveness of HER2-targeted antibody-drug conjugates in treating this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with metastatic bladder cancer.
How similar studies have gone: Other research has shown promising results with HER2-targeted therapies in similar cancer types, indicating potential for success in this novel application.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Iyer, Gopa — Sloan-Kettering Inst Can Research
- Study coordinator: Iyer, Gopa
Related research
Other NIH-funded projects on the same topics.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Improved 3D guidance for kidney-sparing endoscopic UTUC treatment
A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.
-
Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy
This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.
-
Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy
A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.
-
HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer
This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.
-
Treating bladder cancer with ARID1A gene changes
This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.